Every 10-Q that Jasper Therapeutics, Inc. (JSPR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow JSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JSPR filings page.
Jasper Therapeutics, Inc. reported a much smaller net loss for the six months ended June 30, 2026 of $3.9 million, compared with $48.0 million a year earlier. Operating expenses fell to $20.2 million from $48.9 million, reflecting prior restructuring, narrower R&D focus and lower general and administrative costs. Results also benefited from $13.6 million of non‑cash income from remeasuring warrant liabilities and a $2.3 million gain from reversing a CIRM grant liability.
Cash, cash equivalents and restricted cash declined to $7.7 million at June 30, 2026 from $29.1 million at year‑end 2025, after $21.5 million of operating cash outflows in the first half. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months, even after considering cost‑control plans.
Subsequent to quarter‑end, Jasper closed the acquisition of Kira Pharmaceuticals and a related private placement of Non‑Voting Convertible Preferred Stock generating $132.0 million of gross proceeds, and entered into a $12.0 million upfront license agreement with Mirador Therapeutics. The company also put in place a $30.0 million contingent value right tied to a potential Priority Review Voucher for briquilimab.
Jasper Therapeutics (JSPR) filed its Q3 2025 report, highlighting continued losses and liquidity pressure with a going concern warning. The company reported a net loss of $18.7 million for the quarter and $66.7 million for the nine months ended September 30, 2025. Cash and cash equivalents were $50.9 million as of September 30, 2025, while operating cash outflows reached $55.3 million over nine months.
To bolster liquidity, Jasper completed an underwritten offering in September, receiving net proceeds of $27.5 million and issuing 11,670,707 common shares, 675,000 pre-funded warrants, and 12,345,707 common warrants with a $2.92 exercise price. Year to date, it also sold 1,231,447 shares via its ATM for $6.5 million. A new warrant liability of $22.6 million was recognized at quarter end.
Jasper reorganized to extend runway, reducing its workforce by about 50% (20 employees) and recording $1.8 million in restructuring costs. It halted enrollment in its Phase 1b/2a asthma study and discontinued SCID and remaining investigator-sponsored programs to focus on briquilimab in chronic urticaria. Shares outstanding were 27,984,039 as of November 6, 2025.
Jasper Therapeutics reported a net loss of $26.7 million for the quarter and $48.0 million for the six months ended June 30, 2025. Cash and cash equivalents were $39.5 million and total assets declined to $46.5 million from $79.9 million at year-end. Research and development spending rose materially to $21.2 million for the quarter (vs. $11.3 million prior year), driving total operating expenses of $27.1 million.
Management concluded substantial doubt exists about the company's ability to continue as a going concern because existing cash is not sufficient to fund operations for at least twelve months. On July 8, 2025 the company implemented a corporate reorganization, reducing headcount by approximately 50% to focus on its briquilimab mast-cell programs, halting enrollment in the asthma study and discontinuing other programs; estimated severance is approximately $1.9 million. Clinical updates show strong preliminary CSU and CIndU responses but an investigation into a drug product lot is underway and may affect select cohorts.